Alkermes is a biopharmaceutical company focused on neuroscience medicines, including treatments for schizophrenia, bipolar disorder and opioid dependence. It develops and commercializes proprietary and partnered products and has historically emphasized long-acting injectable formulations and drug-delivery science. Customers are primarily specialty physicians, health systems and payers in psychiatry and addiction care.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 306.5 | — | 22.5 | — |
| Q2 2025 | 390.7 | — | 87.1 | — |
| Q3 2025 | 394.2 | — | 82.8 | — |
| Q4 2025 | 384.6 | — | 49.3 | — |
| Q1 2026 | 392.9 | 28.2% | -66.5 | -395.9% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: StoneX Group Inc. (SNEX), Praxis Precision Medicines, Inc. (PRAX), Rush Enterprises, Inc. (RUSHB), Amneal Pharmaceuticals, Inc. (AMRX), Victory Capital Holdings, Inc. (VCTR), Duolingo, Inc. (DUOL)